Posts tagged ‘CAR-T therapy’

Unintentional pioneer: Tim Card is Penn State Cancer Institute’s first patient in cutting-edge cancer treatment

Tim Card and his wife, Tricia, walk the hallways of Penn State Cancer Institute after he receives CAR-T cell therapy infusion. Their backs are toward and the camera, and they are silhouetted against a window. Tricia puts her hand on his back. Tim is pushing an IV pole, and an IV bag with medication hangs from the pole. A rainbow is painted on the window.

Hours after his CAR-T cell therapy infusion, Tim Card and his wife, Tricia, walk the hallways of Penn State Cancer Institute.

By Carolyn Kimmel

Looking back, there were clues that Tim Card would soon be fighting for his life—his body was sending signals that he was misreading.

Because who would ever think a 40-year-old owner of a CrossFit gym and father of seven suddenly would have an aggressive form of cancer?

“I knew I was ‘off,’ but I couldn’t pinpoint it, and it wasn’t all the time. I figured I was just tired,” the Mt. Joy resident said, recalling how he felt in September 2017.

Then, a month later, he got a pain in his side that wouldn’t go away and finally took him to the ER. Had he pulled a muscle? Eaten something that didn’t agree with him?

Five biopsies later, the unfathomable was suddenly real: diffuse large B-cell lymphoma, centered on his left side with cancerous lymph nodes above and below his diaphragm.

(more…)

January 16, 2019 at 10:00 am Leave a comment

Lifesaving lymphoma treatment comes to Penn State Cancer Institute

A graphic of a large, round CAR-T cell with oval-shaped protrusions touching a cancer cell. The cancer cell is round and has tentacles resembling an octopus.

CAR-T cells recognize CD19 antigens on the surface of lymphoma cells as targets for their killing action.

By Abby Sajid

For people with an aggressive form of non-Hodgkin lymphoma, treatments can be limited. Enter a new treatment called Yescarta. Yescarta, or axicabtagene ciloleucel, can be nothing short of “miraculous” for these patients, according to Dr. Shin Mineishi, a medical oncologist at Penn State Cancer Institute. Based on the campus of Penn State Health Milton S. Hershey Medical Center, the Cancer Institute is the only hospital in central Pennsylvania that offers this last-resort treatment for certain cancer patients.

The U.S. Food and Drug Administration (FDA) approved Yescarta in October 2017 for adult patients with a type of non-Hodgkin lymphoma called large B-cell lymphoma if their cancer fails to respond to chemotherapy or returns after two or more treatments. Yescarta is for adult patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

(more…)

December 5, 2018 at 10:30 am Leave a comment


Recent Posts

RSS Penn State Health News

  • An error has occurred; the feed is probably down. Try again later.

Enter your email address to subscribe to Penn State Medicine and receive notifications of new posts by email.

Join 449 other followers

Share This Page

Bookmark and Share

Recent Tweets

Categories